Dosing Regimens For The Treatment Of Fabry Disease
The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease.
1 - 16 . (canceled)
17 . A method of treating Fabry disease in a human subject in need thereof, the method comprising administering from about 50 mg to about 600 mg of 1-deoxygalactonojirimycin, or a pharmaceutically acceptable salt thereof, and an effective amount of α-Gal A enzyme replacement therapy to the subject, wherein the 1-deoxygalactonojirimycin or salt thereof is administered up to about 4 hours prior to, or simultaneously with, the administration of the α-Gal A enzyme replacement therapy.
18 . The method of claim 17 , wherein the amount of 1-deoxygalactonojirimycin or salt thereof administered is from about 150 mg to about 450 mg.
19 . The method of claim 17 , wherein the amount of 1-deoxygalactonojirimycin or salt thereof administered is selected from about 150 mg, about 300 mg and about 450 mg.
20 . The method of claim 17 , wherein the 1-deoxygalactonojirimycin or salt thereof is migalastat hydrochloride.
21 . The method of claim 17 , wherein the subject fasts for a period of time beginning about 0.5 to about 4 hours prior to and ending about 0.5 to about 4 hours following the administration of 1-deoxygalactonojirimycin or salt thereof.
22 . The method of claim 21 , wherein the subject fasts for at least about 2 hours prior to and at least about 2 hours following administration of 1-deoxygalactonojirimycin or salt thereof.
23 . The method of claim 17 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered simultaneously with the α-Gal A enzyme replacement therapy.
24 . The method of claim 17 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered about 2 hours prior to the administration of the α-Gal A enzyme replacement therapy.
25 . The method of claim 17 , wherein the α-Gal A enzyme replacement therapy is a recombinant α-Gal A enzyme.
26 . The method of claim 17 , wherein the α-Gal A enzyme replacement therapy is selected from agalsidase alfa and agalsidase beta.
27 . The method of claim 17 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered as an adjuvant to the α-Gal A enzyme replacement therapy.
28 . The method of claim 17 , wherein the α-Gal enzyme replacement therapy and 1-deoxygalactonojirimycin or salt thereof are administered as a combination therapy.
29 . The method of claim 17 , wherein a second dose of 1-deoxygalactonojirimycin or salt thereof is administered between the administration of the α-Gal A enzyme replacement therapy and about 4 hours thereafter.
30 . The method of claim 17 , wherein the α-Gal enzyme replacement therapy and 1-deoxygalactonojirimycin or salt thereof are administered every 1 to 4 weeks.
31 . The method of claim 17 , wherein the α-Gal enzyme replacement therapy and 1-deoxygalactonojirimycin or salt thereof are administered every 2 weeks.
32 . The method of claim 17 , wherein the 1-deoxygalactonojirimycin or salt thereof is administered orally.
33 . The method of claim 17 , wherein the α-Gal enzyme replacement therapy is administered intravenously.
34 . A method of treating Fabry disease in a human subject in need thereof, the method comprising administering from about 50 mg to about 600 mg of migalastat hydrochloride and an effective amount of α-Gal A enzyme replacement therapy to the subject, wherein the migalastat hydrochloride is administered simultaneously with the α-Gal A enzyme replacement therapy.
35 . The method of claim 34 , wherein the amount of migalastat hydrochloride administered is from about 150 mg to about 450 mg.
36 . The method of claim 34 , wherein the migalastat hydrochloride is administered orally.